细胞疗法领域的合作与授权协议（2016-2025）

本报告全面深入分析了细胞疗法领域的合作与许可协议（2016-2025），并以前所未有的方式呈现了全球领先的生物製药公司签署的细胞疗法相关协议。

这份经过全面修订和更新的报告提供了2016年至2025年细胞疗法交易的详细资讯。

本报告详细分析了企业签署细胞疗法协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，直到最终的商业化。

本报告涵盖了研究、开发、探索和授权方面的合作。

本报告包​​含自2016年以来公布的989项细胞疗法交易的完整列表，其中包括可用的财务条款以及各方披露的实际细胞疗法合作的在线记录链接。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了细胞治疗领域的交易活动。

第一章概述了本报告。

第二章概述了自 2016 年以来的细胞治疗交易活动。

第三章概述了自 2016 年以来主要的细胞治疗交易，并依交易额列出。

第四章提供了最活跃的 25 家细胞治疗公司的完整清单及其简要概述，以及细胞治疗交易和公开合约文件的完整清单。

第五章对自 2016 年 1 月以来已完成和已宣布的、合约文件公开的细胞治疗交易进行了全面深入的审查。

第六章对自2016年1月以来签署和公布的细胞疗法合作协议进行了全面深入的回顾。本章以具体的细胞疗法技术类型进行组织。

该报告还包含大量表格和图表，展示了自2016年以来细胞疗法交易的趋势和活动。

此外，我们还提供了一个全面的合约目录，依公司名称（A-Z）、合约类型和疾病治疗进行分类。每个合约标题都透过网路连结连结到线上合约记录，并在可用的情况下连结到合约文件，方便用户轻鬆存取每个合约文件。

主要优势

"细胞疗法合作与授权协议（2016-2025）" 报告为读者提供以下主要优势：

• 了解自 2016 年以来的交易趋势
• 查看细胞疗法合作与许可协议（2016-2025）
• 基准分析 - 确定交易市场价值
• 财务条款 - 首付款、里程碑付款、特许权使用费
• 依公司（A-Z）、交易类型和治疗领域列出交易
• 以价值为排名的热门交易
• 最活跃的交易撮合者
• 识别每笔交易的资产描述和条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性
• 节省数百小时的研究时间。

范围

• "细胞疗法合作与许可协议（2016-2025）" 旨在帮助读者深入了解细胞疗法的发展趋势以及全球领先的生物製药公司所达成的协议结构。

本报告内容

• 生物製药产业细胞疗法交易趋势
• 製药和生物技术公司细胞疗法交易记录目录
• 以价值排名主要的细胞疗法交易
• 最活跃的细胞疗法许可协议公司
• "细胞疗法合作与许可协议（2016-2025）" 提供对现有交易记录的全面访问，包括合约文件（如有）。

分析合约有助于对以下方面进行尽职调查：

• 合约具体授予或选择哪些权利？
• 合约实际授予合作伙伴哪些权利？
• 授予了哪些排他性权利？
• 交易的付款结构是什么？
• 如何进行销售和付款审计？
• 合约期限是多久？
• 如何定义合约的关键条款？
• 如何处理并拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果所有权发生变更，会发生什么事？
• 如何就分授权和分包条款达成协议？
• 贵公司要求使用哪些标准条款？
• 哪些标准条款会因交易对手或交易类型而异？
• 贵公司必须遵守哪个司法管辖区的法律？

目录

摘要整理

第一章：引言

第二章：细胞疗法交易趋势

• 引言
• 历年细胞疗法交易
• 最活跃的细胞疗法经销商
• 以交易类型划分的细胞疗法交易
• 依治疗领域划分的细胞疗法交易
• 依行业划分的细胞疗法交易
• 细胞疗法交易条款
  • 细胞疗法交易的关键价值
  • 细胞疗法交易中的预付款
  • 细胞疗法交易中的里程碑付款
  • 细胞疗法特许权使用费率

第三章 - 关键细胞疗法交易

• 引言
• 以价值排名的顶级细胞疗法交易

第四章 - 最活跃的细胞疗法经销商

• 引言
• 最活跃的细胞疗法经销商
• 最活跃的细胞疗法经销商公司简介

第五章 - 细胞疗法合约交易目录

• 引言
• 细胞疗法合约交易目录

第六章 - 依技术类型分类的细胞疗法交易

• 交易目录
• 依公司分类的细胞疗法交易目录 (AZ)
• 以交易类型分类的细胞疗法交易目录
• 依治疗领域分类的细胞疗法交易目录
• 交易类型定义
• 关于研究公司
• 当前合作伙伴关係
• 当前协议
• 当前合作伙伴关係近期报告标题

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 989 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cell therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:

• Trends in cell therapy dealmaking in the biopharma industry
• Directory of cell therapy deal records covering pharmaceutical and biotechnology
• The leading cell therapy deals by value
• Most active cell therapy licensing dealmakers
• Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

• 2.1. Introduction
• 2.2. Cell therapy deals over the years
• 2.3. Most active cell therapy dealmakers
• 2.4. Cell therapy deals by deal type
• 2.5. Cell therapy deals by therapy area
• 2.6. Cell therapy deals by industry sector
• 2.7. Deal terms for cell therapy deals
  • 2.7.1 Cell therapy deals headline values
  • 2.7.2 Cell therapy deal upfront payments
  • 2.7.3 Cell therapy deal milestone payments
  • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

• 3.1. Introduction
• 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

• 4.1. Introduction
• 4.2. Most active cell therapy dealmakers
• 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

• Deal directory
• Deal directory - Cell therapy deals by company A-Z
• Deal directory - Cell therapy deals by deal type
• Deal directory - Cell therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cell therapy deals since 2016
• Figure 2: Active cell therapy dealmaking activity - 2016 - 2025
• Figure 3: Cell therapy deals by deal type since 2016
• Figure 4: Cell therapy deals by therapy area since 2016
• Figure 5: Cell therapy deals by industry sector since 2016
• Figure 6: Cell therapy deals with a headline value
• Figure 7: Cell therapy deals with an upfront value
• Figure 8: Cell therapy deals with a milestone value
• Figure 9: Cell therapy deals with a royalty rate value
• Figure 10: Top cell therapy deals by value since 2016
• Figure 11: Most active cell therapy dealmakers 2016 - 2025
• Figure 12: Cell therapy deals by technology type since 2016